A carregar...
First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
Ovarian cancer is the fifth most common cause of cancer death in women in Europe. Despite the progress, almost 70% of the patients relapse. The standard treatment is cytoreductive surgery followed by platinumtaxane chemotherapy; in patients with a disseminated disease, one option is neoadjuvant chem...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6371937/ https://ncbi.nlm.nih.gov/pubmed/30799939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S155425 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|